"We believe Illumina is using the courts to retaliate against us for registering concerns about the antitrust implications of Illumina's acquisition of Grail—another provider of blood-based cancer tests—and in an attempt to slow us down in the marketplace as we get ready to launch our blood test to screen for early signs of colorectal cancer," Guardant's general counsel, John Saia, said in a statement.